Azitra Corp - רווח נקי למניה בארבעת הרבעונים האחרונים AZTR
The development of Azitra, Inc. (AZTR) depends on the outcomes of genetically modified bacteria tests, which necessitates strict budget control. Diversification of hubs for transporting dermatological products mitigates operational risks. Robots analyzing the skin microbiome enhance research efficiency. The YoY ttm change in net income per share from GURU.Markets is derived from this chart, where the 87.40 level captures the latest values.
Azitra Corp - פילוחים אנליטיים ומדדי מפתח (AZTR)
Analyzing business resilience to market downturns requires verification of actual profits. Azitra, Inc. (AZTR) has no commercial sales, existing on external capital to develop dermatological drugs. This annual percentage growth chart of EPS TTM measures the dynamics of net income per share over 12 months, identifying operating margin expansion. For a clinical-stage biotech, this indicator often shows negative values. Blindly trusting such figures without considering financing carries the risk of a drawdown.
